Peptides DB
Research-centric peptide and protocol reference hub
Study 23 of 23Degarelix literatureFrontiers in endocrinology · ObservationalHigh-impact journal2026

GnRH antagonist-induced ovarian suppression does not protect the ovarian reserve from cyclophosphamide chemotherapy in tumour-bearing mice.

Degarelix does not appear to protect ovarian function from damage caused by cyclophosphamide chemotherapy in mice, raising questions about its clinical utility in this setting.

Read at Frontiers in endocrinologyAdd to compare

Where it sits

this study against the rest of the degarelix corpus
1
Preclinical
20
Observational · this one
0
Open-label
2
Randomised
0
Reviews

Summary and findings

This study evaluated the effects of the GnRH antagonist degarelix on ovarian function in tumour-bearing mice undergoing cyclophosphamide chemotherapy. The study measured ovarian volume, corpora lutea number, and serum anti-Müllerian hormone (AMH) levels. Results indicated that degarelix did not protect against chemotherapy-induced ovarian damage.

How much of this paper we could read: full text read (0.80). We had a clear abstract, so the summary below closely tracks the paper. What this means →
Not reported in abstract.2026

Abstract

The authors’ words, as Frontiers in endocrinology supplied them

<h4>Background</h4>Gonadotropin-releasing hormone (GnRH) analogues are used clinically to induce ovarian suppression during chemotherapy treatment and are proposed to protect the ovaries from chemotherapy-induced damage, yet their efficacy and underlying mechanisms remain uncertain. While most preclinical and clinical studies have focused on GnRH agonists, far less is known about the effects of GnRH antagonists in this context, despite their more rapid and direct suppression of gonadotrophin signaling.<h4>Materials and methods</h4>We used the GnRH antagonist degarelix to induce ovarian suppression in an orthotopic tumour-bearing mouse model. We then evaluated whether degarelix protected against cyclophosphamide-induced ovarian damage in reproductively young and aged mice receiving one or two chemotherapy doses. Ovarian function was assessed by quantifying ovarian volume, corpora lutea number (a marker of ovulation), and serum anti-Müllerian hormone (AMH) levels, as well as follicle enumeration and histological assessment of ovarian fibrosis.<h4>Results</h4>Degarelix suppressed ovulatory activity, as indicated by reduced corpora lutea number and ovarian volume. However, degarelix was associated with increased ovarian fibrosis in young mice treated with single-dose cyclophosphamide and failed to protect the ovarian reserve following either single or two doses of cyclophosphamide in both age groups. Moreover, degarelix did not prevent reductions in circulating AMH, with all treatment groups displaying reduced AMH levels compared with controls in young mice.<h4>Conclusions</h4>Together, our findings do not support a protective effect of GnRH antagonist treatment against cyclophosphamide-induced ovarian damage.

Background

Not reported in abstract.

Methods

Not reported in abstract.

Results

Not reported in abstract.

Interpretation

Not reported in abstract.

Limitations

Not reported in abstract.

Elsewhere in the Degarelix corpus

BExploration of cardiac adverse events associated with relugolix and degarelix: a multi-center pharmacovigilance study based on the FAERS database.Expert opinion on drug safety · 2025 · ROR for electrocardiogram abnormality with relugolix was 77.54.reviewDExploration of cardiac adverse events associated with relugolix and degarelix: a multi-center pharmacovigilance study based on the FAERS database.Expert opinion on drug safety · 2026 · ROR for electrocardiogram abnormality with relugolix was 77.54.reviewBInterstitial lung disease associated with antiandrogen agents: a pharmacovigilance study based on FDA adverse event reporting system.International urology and nephrology · 2024 · n=761 · 761 cases of ILD associated with antiandrogen agents were analyzed.reviewAEffect of neoadjuvant androgen deprivation therapy on prostate and tumor morphology prior to MRI-guided transurethral ultrasound ablation of prostate cancer.International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group · 2026 · n=15 · PSA declined by 87% (-7.6 ng/mL; 95% CI. -9.7 to -5.7; p < 0.001)HumanBFewer Injections and Lower Drug Costs With Long-Acting GnRH Depot Formulations: A Nationwide Analysis of 2.3 Million Patient-Years in Japan.Cancer reports (Hoboken, N.J.) · 2026 · n=2276025 · Injections decreased by 21.5%, from 1,275,081 to 1,000,324.HumanBFewer Injections and Lower Drug Costs With Long-Acting GnRH Depot Formulations: A Nationwide Analysis of 2.3 Million Patient-Years in Japan.Cancer reports (Hoboken, N.J.) · 2023 · n=2276025 · Injections decreased by 21.5%, from 1,275,081 to 1,000,324.Human